Pharvaris (PHVS) to Release Earnings on Tuesday

Pharvaris (NASDAQ:PHVS – Get Free Report) will likely be issuing its Q2 2026 results after the market closes on Tuesday, August 11th. Analysts expect the company to announce earnings of ($0.7467) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 12:30 PM ET.

Pharvaris (NASDAQ:PHVS – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. On average, analysts expect Pharvaris to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Get Pharvaris alerts:

Pharvaris Trading Up 3.5%

Shares of PHVS stock traded up $1.14 during trading hours on Tuesday, hitting $33.39. 71,697 shares of the company were exchanged, compared to its average volume of 292,032. Pharvaris has a 52 week low of $19.56 and a 52 week high of $36.60. The business has a 50 day moving average of $32.89 and a two-hundred day moving average of $29.60. The company has a market capitalization of $2.18 billion, a PE ratio of -10.47 and a beta of -2.31.

Insider Buying and Selling

In related news, CFO David W. Nassif sold 10,000 shares of the firm’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $30.31, for a total value of $303,100.00. Following the completion of the transaction, the chief financial officer directly owned 120,300 shares of the company’s stock, valued at approximately $3,646,293. This trade represents a 7.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Anne Lesage sold 27,872 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.48, for a total transaction of $988,898.56. Following the completion of the sale, the insider owned 58,750 shares of the company’s stock, valued at approximately $2,084,450. This represents a 32.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 178,322 shares of company stock worth $5,969,286 in the last quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its position in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the period. Barclays PLC bought a new position in shares of Pharvaris in the fourth quarter valued at about $77,000. Public Employees Retirement System of Ohio lifted its stake in shares of Pharvaris by 39.3% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 6,269 shares of the company’s stock worth $156,000 after buying an additional 1,769 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after buying an additional 1,695 shares during the last quarter. Finally, Alliancebernstein L.P. bought a new stake in shares of Pharvaris during the 3rd quarter worth about $224,000.

Wall Street Analyst Weigh In

A number of analysts have recently commented on PHVS shares. Royal Bank Of Canada cut their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Morgan Stanley boosted their target price on Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a research note on Thursday, June 25th. UBS Group set a $74.00 price target on Pharvaris in a research report on Wednesday, May 13th. Wolfe Research initiated coverage on shares of Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price objective on the stock. Finally, Wall Street Zen lowered shares of Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pharvaris has an average rating of “Moderate Buy” and an average price target of $50.08.

View Our Latest Analysis on PHVS

About Pharvaris

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

Featured Articles

• Five stocks we like better than Pharvaris
• Apple’s AI Strategy Looks Different—Will It Pay Off?
• The AI Chip Stock Making a Quiet Move Toward Dominance
• Why Walmart and Amazon Could Be the Market’s Most Complementary Mega-Caps
• Dodging Deutsche Telekom: T-Mobile’s Strategic Win

Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.